UGC Corazón, Hospital Universitario Virgen de la Victoria, Instituto de Biomedicina de Málaga, CIBERCV Enfermedades Cardiovasculares, Universidad de Málaga, Spain
The Department of Cardiovascular Diseases and Department of Health Sciences Research, Mayo Clinic, Rochester, MN.
J Am Heart Assoc. 2017 Oct 11;6(10):e006404. doi: 10.1161/JAHA.117.006404.
Participation in cardiac rehabilitation (CR) is an essential component of care for patients with coronary artery disease. However, little is known about its benefit on cardiovascular outcomes in patients with diabetes mellitus (DM) who have undergone percutaneous coronary intervention. The aim of our study was to evaluate the impact of CR in this high-risk group of patients.
We performed a retrospective analysis of all patients with DM who underwent percutaneous coronary intervention in Olmsted County (Minnesota) between 1994 and 2010, assessing the impact of CR participation on clinical outcomes. CR participation was significantly lower in patients with DM (38%, 263/700) compared with those who did not have DM (45%, 1071/2379; =0.004). Using propensity score adjustment, we found that in patients with DM, CR participation was associated with significantly reduced all-cause mortality (hazard ratio, 0.56; 95% confidence interval, 0.39-0.80; =0.002) and composite end point of mortality, myocardial infarction, or revascularization (hazard ratio, 0.77; 95% confidence interval, 0.60-0.98; =0.037), during a median follow-up of 8.1 years. In patients without DM, CR participation was associated with a significant reduction in all-cause mortality (hazard ratio, 0.67; 95% confidence interval, 0.55-0.82; <0.001) and cardiac mortality (hazard ratio, 0.67; 95% confidence interval, 0.47-0.95; =0.024).
CR participation after percutaneous coronary intervention is associated with lower all-cause mortality rates in patients with DM, to a similar degree as for those without DM. However, CR participation was lower in patients with DM, suggesting the need to identify and correct the barriers to CR participation for this higher-risk group of patients.
参与心脏康复(CR)是冠心病患者治疗的重要组成部分。然而,对于接受经皮冠状动脉介入治疗的糖尿病(DM)患者,其对心血管结局的益处知之甚少。我们的研究目的是评估 CR 对这一高危患者群体的影响。
我们对 1994 年至 2010 年间在明尼苏达州奥姆斯特德县(Olmsted County)接受经皮冠状动脉介入治疗的所有 DM 患者进行了回顾性分析,评估了 CR 参与对临床结局的影响。与没有 DM 的患者(45%,1071/2379)相比,DM 患者的 CR 参与率明显较低(38%,263/700;=0.004)。通过倾向评分调整,我们发现 DM 患者中,CR 参与与全因死亡率显著降低相关(风险比,0.56;95%置信区间,0.39-0.80;=0.002),以及死亡率、心肌梗死或血运重建的复合终点(风险比,0.77;95%置信区间,0.60-0.98;=0.037),中位随访 8.1 年。在没有 DM 的患者中,CR 参与与全因死亡率显著降低相关(风险比,0.67;95%置信区间,0.55-0.82;<0.001)和心脏死亡率(风险比,0.67;95%置信区间,0.47-0.95;=0.024)。
经皮冠状动脉介入治疗后,CR 参与与 DM 患者的全因死亡率降低相关,其程度与没有 DM 的患者相似。然而,DM 患者的 CR 参与率较低,这表明需要确定并纠正这一高危患者群体参与 CR 的障碍。